Positive initial MDMA-analogue screening results
Filed with ASX · · 3 pages · English
● 66 of the 68 sent compounds screened demonstrated no interactions with the selected anti-targets (receptors and enzymes known to be involved in unwanted side effects) ● Second batch of compounds from the original analogue library of > 100 compounds now being prepared for initial screening ● First patent family successfully filed, further IP generation underway ● New MDMA analogues are now being c
Story so far
Earlier from Emyria
- Emyria receives $1,162,000 R&D Tax Incentive Refund
- Emyria Welcomes Tattarang as Strategic Investor
- MDMA Analogue Development Milestone
- Emyria selected to join Palantirs Foundry Builders Program
- Novel MDMA Analogue Screening Program Advanced
Later from Emyria
- Positive animal data for Emyrias ultra-pure CBD capsule
- Pause in Trading
- Emyria adds wearables to psychedelic-assisted therapy trials
- Notification regarding unquoted securities - EMD
- Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria